| Journal | JAMA network open |
| Study Type | Clinical Study |
| Population | Human participants |
Pregnant patients increasingly turn to cannabis retailers for medical advice, yet these staff members lack clinical training to provide evidence-based guidance on prenatal cannabis safety. This study reveals a critical gap in the information ecosystem that could influence maternal and fetal health decisions.
This cross-sectional study used mystery shoppers to evaluate advice given by California cannabis retailers (budtenders) to pregnant individuals inquiring about prenatal cannabis, blunt, and tobacco use safety. The study examined whether recommendations varied based on mental health indications versus general use, and assessed differences between storefront and delivery services. The research highlights the disconnect between retail cannabis advice and established medical evidence regarding prenatal substance use risks.
“This study confirms what I observe clinically—patients are seeking cannabis guidance from retail staff who are neither trained nor qualified to provide medical advice, particularly regarding pregnancy safety. The retail environment creates a false sense of medical authority that can lead to potentially harmful decisions.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Should healthcare providers be concerned about patients receiving cannabis advice from budtenders during pregnancy?
Yes, this study reveals that pregnant individuals may view budtenders as trusted sources of information about prenatal cannabis use safety. Healthcare providers should proactively discuss cannabis use with pregnant patients, as budtenders lack medical training and may provide advice that conflicts with clinical guidelines.
What makes budtender advice particularly concerning for pregnant patients?
Budtenders are retail employees without medical training who may have financial incentives to recommend products. This study demonstrates they provide guidance on prenatal substance use safety, including tobacco and cannabis, despite lacking the clinical expertise to assess maternal and fetal risks.
How should clinicians address prenatal cannabis use when patients mention budtender recommendations?
Clinicians should provide non-judgmental, evidence-based counseling about the potential risks of prenatal cannabis exposure to fetal development. It’s important to acknowledge patient concerns while clearly distinguishing between retail advice and medical recommendations based on current research.
Does the indication for cannabis use affect the safety advice budtenders provide to pregnant customers?
The study examined whether budtender recommendations varied based on mental health versus other indications for use. This suggests that budtenders may tailor their advice based on perceived medical need, despite lacking clinical training to make such determinations.
What patient safety implications does this study highlight for prenatal care?
This research underscores the need for enhanced communication between healthcare providers and pregnant patients about cannabis use. Providers should create safe spaces for discussing substance use and ensure patients receive accurate, medically-informed guidance rather than relying on retail recommendations.
